U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07739966) titled 'A Study of DS-3939a in Participants With Solid Tumors' on July 28.
Brief Summary: The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Locally Advanced Non-Small Cell Lung Cancer
Metastatic Non-Small Cell Lung Cancer
Intervention:
DRUG: DS-3939a
DS-3939a will be administered as an IV infusion.
DRUG: Pembrolizumab
Pembrolizumab will be administered as an IV infusion.
DRUG: Carboplatin
Carboplatin will be ad...